BEAM 8-K: Press Release Furnished for Quarter Ended June 30, 2025

Rhea-AI Filing Summary

Report type: Current Report on Form 8-K dated August 5, 2025 by Beam Therapeutics Inc. (BEAM).

On August 5, 2025 the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The filing states that the information and Exhibit 99.1 are being furnished (not "filed") for purposes of the Exchange Act and are not subject to Section 18 liability except by specific reference.

Corporate details: Beam Therapeutics Inc., Delaware, principal office 238 Main Street, Cambridge, MA 02142; common stock trades as BEAM on Nasdaq Global Select Market. Form signed by John Evans, Chief Executive Officer.

Positive

• Press release furnished to investors announcing Q2 2025 results (Exhibit 99.1).
• Timely disclosure: 8-K filed on the same date as the press release (August 5, 2025).

Negative

• No financial metrics included in the 8-K text; investors must consult Exhibit 99.1 for details.
• Information furnished, not filed, which may limit legal incorporation in subsequent filings.

Insights

Financial Analyst

TL;DR: Routine earnings release furnished as Exhibit 99.1; the 8-K contains no financial metrics itself, limiting immediate analytical action.

The filing notifies investors that Beam released its Q2 2025 results via a press release furnished on August 5, 2025. Because the 8-K does not include the actual financial figures, this filing functions as a distribution notice rather than a disclosure vehicle for metrics. Investors and analysts must review Exhibit 99.1 to assess revenue, EPS, guidance, or margin changes. The document also clarifies the exhibit is "furnished" and not "filed," which has evidentiary implications under Section 18.

Corporate Governance Expert

TL;DR: Filing is procedurally standard; signature by CEO and furnished exhibit follow typical disclosure practice.

The Form 8-K meets procedural requirements by furnishing the press release as Exhibit 99.1 and including the required Item 2.02 and Item 9.01 disclosures. The company explicitly states the release is furnished and not filed, reducing automatic incorporation risk. The form is signed by the CEO, indicating appropriate officer attestation. No governance concerns or material admissions appear in the text provided.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false000174599900017459992025-08-052025-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

BEAM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39208		81-5238376
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)
238 Main Street
Cambridge, MA				02142
(Address of principal executive offices)				(Zip Code)

(Registrant’s telephone number, including area code): (857) 327-8775

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	BEAM	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2025, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release Issued by Beam Therapeutics Inc. on August 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BEAM THERAPEUTICS INC.
Date: August 5, 2025		By:	/s/ John Evans
		Name:	John Evans
		Title:	Chief Executive Officer

FAQ

When did Beam Therapeutics (BEAM) file this 8-K?

The 8-K is dated and filed on August 5, 2025.

What did the 8-K announce for BEAM?

The 8-K states the Company issued a press release announcing financial results for the quarter ended June 30, 2025.

Is the press release in the 8-K filed or furnished?

The press release is furnished as Exhibit 99.1 and the filing specifies the information is furnished, not filed.

Where can I find the press release referenced in the 8-K?

The press release is attached to the Form 8-K as Exhibit 99.1; consult the exhibit for full financial details.

Who signed the 8-K for Beam Therapeutics?

The Form 8-K is signed by John Evans, Chief Executive Officer, dated August 5, 2025.